The class II trans-activator CIITA interacts with the TBP-associated factor TAFII32
about
Enhancement of CIITA transcriptional function by ubiquitinHistone deacetylase 1/mSin3A disrupts gamma interferon-induced CIITA function and major histocompatibility complex class II enhanceosome formationZXDC, a novel zinc finger protein that binds CIITA and activates MHC gene transcriptionThe zinc finger proteins ZXDA and ZXDC form a complex that binds CIITA and regulates MHC II gene transcriptionAnalysis of ankyrin repeats reveals how a single point mutation in RFXANK results in bare lymphocyte syndromeCIITA leucine-rich repeats control nuclear localization, in vivo recruitment to the major histocompatibility complex (MHC) class II enhanceosome, and MHC class II gene transactivationClass II transactivator: mastering the art of major histocompatibility complex expressionInterferon gamma repression of collagen (COL1A2) transcription is mediated by the RFX5 complexThe RFX family interacts at the collagen (COL1A2) start site and represses transcriptionRegulation of human immunodeficiency virus type 1 gene expression by clade-specific Tat proteins.Acetylation by PCAF enhances CIITA nuclear accumulation and transactivation of major histocompatibility complex class II genes.Two distinct gamma interferon-inducible promoters of the major histocompatibility complex class II transactivator gene are differentially regulated by STAT1, interferon regulatory factor 1, and transforming growth factor betaTwo distinct domains within CIITA mediate self-association: involvement of the GTP-binding and leucine-rich repeat domainsSelf-association of CIITA and its transactivation potential.Promoter-specific functions of CIITA and the MHC class II enhanceosome in transcriptional activationDysregulated recruitment of the histone methyltransferase EZH2 to the class II transactivator (CIITA) promoter IV in breast cancer cells.Novel functions for TAF7, a regulator of TAF1-independent transcription.Gene-specific factors determine mitotic expression and bookmarking via alternate regulatory elements.Transcriptional regulation by Modulo integrates meiosis and spermatid differentiation in male germ line.Comparison of immunological characteristics of mesenchymal stem cells derived from human embryonic stem cells and bone marrow.Degradation, Promoter Recruitment and Transactivation Mediated by the Extreme N-Terminus of MHC Class II Transactivator CIITA Isoform IIICIITA stimulation of transcription factor binding to major histocompatibility complex class II and associated promoters in vivo.CIITA and Its Dual Roles in MHC Gene Transcription.Impaired class II transactivator expression in mice lacking interferon regulatory factor-2.Self-association of class II transactivator correlates with its intracellular localization and transactivation.The MHC class II transactivator (CIITA) requires conserved leucine charged domains for interactions with the conserved W box promoter element.Differential expression of HLA class II genes associated with disease susceptibility and progression in rheumatoid arthritis.Role of Sug1, a 19S proteasome ATPase, in the transcription of MHC I and the atypical MHC II molecules, HLA-DM and HLA-DO.Interactions between the class II transactivator and CREB binding protein increase transcription of major histocompatibility complex class II genes.Downregulation of CIITA function by protein kinase a (PKA)-mediated phosphorylation: mechanism of prostaglandin E, cyclic AMP, and PKA inhibition of class II major histocompatibility complex expression in monocytic linesInvolvement of CREB binding protein in expression of major histocompatibility complex class II genes via interaction with the class II transactivator.Kinetics of a gamma interferon response: expression and assembly of CIITA promoter IV and inhibition by methylation.The class II transactivator requires brahma-related gene 1 to activate transcription of major histocompatibility complex class II genes.Gamma interferon-dependent transcriptional memory via relocalization of a gene locus to PML nuclear bodies.CIITA regulates transcription onset viaSer5-phosphorylation of RNA Pol II.CIITA mediates interferon-gamma repression of collagen transcription through phosphorylation-dependent interactions with co-repressor molecules.Sequential modifications in class II transactivator isoform 1 induced by lipopolysaccharide stimulate major histocompatibility complex class II transcription in macrophages.Defective class II transactivator expression in a B lymphoma cell line.Combinations of dominant-negative class II transactivator, p300 or CDK9 proteins block the expression of MHC II genes.MHC class II-deficient tumor cell lines with a defective expression of the class II transactivator.
P2860
Q22330796-CCA2E289-6CBA-44CF-AB25-088C59FF4325Q24289051-67F25413-427D-494B-8E29-35CDFB00B1B0Q24289418-F638B198-58E0-4AC8-AA34-34B8E6975F8EQ24305248-4B207A08-28E6-4AF9-A646-906642923CB4Q24550882-E56F1B53-DD3D-468D-871A-BF620CAA3B54Q24551176-A907DD58-DFE4-4471-AE7C-BF996EC70BAFQ24552298-AFCEDF78-95AA-4773-B4D9-23A9C395BD10Q28206220-F7465607-CC33-4BB4-BA99-33BB4A11B67AQ28216325-8CE1F2BF-9FAF-42D5-B0AD-0C1437888EC0Q30350982-39DD5331-3981-43EA-905D-EE4CC13C2C90Q33605603-E3DB748C-3C12-4DE3-BD16-E483B8EA0FECQ33957154-E6701210-C425-4CAA-BBAB-F0A86594706FQ33967979-789E672B-453A-48F2-8BDC-0593BD370624Q33969017-9294C296-2C52-44DE-9F80-9302099DA5CCQ34086182-D4E2A28B-0C58-41B9-8C56-EFDCB106C005Q34259906-B8C7C8E5-8724-43B3-A6C0-E1F821E66FACQ34385864-37AF8C5E-8973-48DC-A555-A372332A9E21Q34502167-EE97A5AF-9371-4C17-9FD7-F19C9BCE34A2Q35033134-D5EE1ECB-A4F4-4F25-B057-9A05E04FD8F1Q35100235-C618AA4A-F592-4F86-A91B-59C2AF478769Q35922077-5ABA703B-6A6E-4925-82F6-225F306313A7Q37395250-19792932-42BC-416E-8F41-C1740D8919C1Q37405448-91E03E17-57F3-4E35-87E4-9CB738860E25Q38298691-E8028542-1B91-4469-879B-92F03A22590BQ38299750-F7E0F16C-A74E-4702-8B99-8D9ABB3506CDQ38333945-6285A6FE-64FF-4C6C-8A02-32D5A2421659Q38349267-8C4112EA-53B4-4B08-8E2B-102A13999812Q39318369-DDD5D9DC-9A98-4A37-8F21-754E278E8FEEQ39444652-E542E748-F993-4BA8-A47F-01C498D2748BQ39459892-E03B2094-9B64-4C64-B277-AC05FC81E21BQ39576629-689E29D3-75D3-4F3B-908D-407FC7846707Q39674999-30C64EA6-1791-4789-93A4-D0EFAB4D5928Q39695544-0F11C6EE-A26E-43AF-85E4-26B1F9678DABQ39897951-51AC7FE2-E6F9-44E0-BFFD-0147ED9D05FFQ39927810-8C937423-AE68-4798-A830-EB66CB82BDCFQ40054485-7DC1FFDE-1223-477D-AAB0-772FD0C1E84DQ40210146-CB5F94CE-DF22-4ED0-BB0A-8F31766D62B9Q40587933-30FFBB84-3DAE-4557-8AFF-A315690BCA76Q40699713-2BE084BD-C001-4423-838D-E748805CB26DQ40735560-2328B67A-A1AB-433A-B4D8-850ADBA9D775
P2860
The class II trans-activator CIITA interacts with the TBP-associated factor TAFII32
description
1997 nî lūn-bûn
@nan
1997 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
The class II trans-activator CIITA interacts with the TBP-associated factor TAFII32
@ast
The class II trans-activator CIITA interacts with the TBP-associated factor TAFII32
@en
The class II trans-activator CIITA interacts with the TBP-associated factor TAFII32
@en-gb
The class II trans-activator CIITA interacts with the TBP-associated factor TAFII32
@nl
type
label
The class II trans-activator CIITA interacts with the TBP-associated factor TAFII32
@ast
The class II trans-activator CIITA interacts with the TBP-associated factor TAFII32
@en
The class II trans-activator CIITA interacts with the TBP-associated factor TAFII32
@en-gb
The class II trans-activator CIITA interacts with the TBP-associated factor TAFII32
@nl
prefLabel
The class II trans-activator CIITA interacts with the TBP-associated factor TAFII32
@ast
The class II trans-activator CIITA interacts with the TBP-associated factor TAFII32
@en
The class II trans-activator CIITA interacts with the TBP-associated factor TAFII32
@en-gb
The class II trans-activator CIITA interacts with the TBP-associated factor TAFII32
@nl
P2860
P921
P356
P1476
The class II trans-activator CIITA interacts with the TBP-associated factor TAFII32
@en
P2093
P2860
P304
P356
10.1093/NAR/25.12.2522
P407
P577
1997-06-01T00:00:00Z